Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 95,000 Shares of Stock

Key Points

• Illumina director Keith Meister sold 95,000 shares at an average price of $203.29, generating approximately $19.3 million. His remaining direct holdings declined 4.55% to 1,994,425 shares.
• Illumina shares recently traded at $219.40, near their 52-week high of $220.43, with the stock’s 50-day and 200-day moving averages at $188.01 and $152.44, respectively.
• The company exceeded quarterly expectations, reporting $1.31 in EPS and $1.16 billion in revenue, while analysts’ consensus rating remains “Hold” with an average price target of $188.40.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 95,000 shares of Illumina stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $203.29, for a total transaction of $19,312,550.00. Following the transaction, the director directly owned 1,994,425 shares in the company, valued at approximately $405,446,658.25. This represents a 4.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Illumina Stock Performance

ILMN traded up $6.16 during trading on Friday, hitting $219.40. 1,917,079 shares of the company traded hands, compared to its average volume of 2,061,622. The firm has a market cap of $33.13 billion, a P/E ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45. The stock's fifty day moving average is $188.01 and its 200 day moving average is $152.44. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a one year low of $88.00 and a one year high of $220.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

Institutional investors have recently made changes to their positions in the business. Elyxium Wealth LLC purchased a new stake in Illumina during the fourth quarter valued at about $25,000. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina in the fourth quarter worth about $26,000. Laurel Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $26,000. Fiduciary Financial Advisors bought a new position in Illumina during the 2nd quarter worth approximately $26,000. Finally, Activest Wealth Management increased its stake in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after purchasing an additional 215 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. TD Cowen boosted their price target on shares of Illumina from $192.00 to $210.00 and gave the company a "hold" rating in a research report on Friday, July 31st. Canaccord Genuity Group increased their price objective on Illumina from $190.00 to $205.00 and gave the stock a "hold" rating in a research report on Monday, August 3rd. Daiwa Securities Group upgraded Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Sanford C. Bernstein restated a "market perform" rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Finally, Zacks Research upgraded Illumina from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $188.40.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source